Northstrive Biosciences已正式宣布，其EL-32工作细胞库成功运抵美国。与此同时，公司与Modulant Biosciences展开合作，正式启动了针对双重肌生长抑制素资产的生产工艺优化项目。该项目核心目标在于，通过优化制造流程，开发能够与GLP-1疗法协同作用、专注于肌肉保护的新型疗法。
Northstrive Biosciences已正式宣布，其EL-32工作细胞库成功运抵美国。与此同时，公司与Modulant Biosciences展开合作，正式启动了针对双重肌生长抑制素资产的生产工艺优化项目。该项目核心目标在于，通过优化制造流程，开发能够与GLP-1疗法协同作用、专注于肌肉保护的新型疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.